New York is currently home to 4446 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Problem-Solving Training for Concussion
Recruiting
Mild traumatic brain injury (mTBI), also known as concussion, is a common injury sustained by Veterans. While most individuals who sustain mTBI experience a complete recovery within several weeks of injury, many Veterans with history of mTBI report frequent and long-lasting neurobehavioral complaints and functional impairment. Though research suggests that these outcomes are strongly influenced by co-occurring conditions such as post-traumatic stress disorder, depression, and chronic pain, evide... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: VA Western New York Healthcare System, Buffalo, NY, Buffalo, New York
Conditions: Brain Concussion
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
Recruiting
The main aim of this study is to evaluate the PK, safety, tolerability and immunogenicity of subcutaneous (SC) administration of TAK-881 in adult and pediatric participants with PIDD and compare them to HYQVIA in participants 16 years old and older. The participants will be treated with TAK-881/HYQVIA or HYQVIA/TAK-881 with the same dose and dosing interval of immunoglobulin for up to 51 weeks (for participants greater than or equal to \[\>=\]16 years) and only with TAK-881 for up to 27 weeks (... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
10/04/2024
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Primary Immunodeficiency Diseases (PID)
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Local Institution - 017-080, Babylon, New York
Conditions: Advanced NSCLC, Metastatic Lung Cancer
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Recruiting
The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studies may participate the FLOTILLA study if they are still benefiting from the use of the study medicines. This will be determined by the study doctor. People may not participate in the FLOTILLA study if... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Rockefeller Outpatient Pavilion (53rd Street), New York, New York
Conditions: Solid Tumors
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
Recruiting
The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
10/04/2024
Locations: Weill Cornell Medicine, New York, New York
Conditions: Alzheimer Disease
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
Recruiting
This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Erie County Medical Center, Buffalo, New York
Conditions: Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Add-on Reparixin in Adult Patients With ARDS
Recruiting
Study objectives 1. To characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to severe ARDS (PaO2/FIO2 ratio ≤ 200). 2. to assess the effect of reparixin on systemic biomarkers linked to a hyper-inflammatory ARDS phenotype. 3. To evaluate the safety of reparixin vs. placebo in patients enrolled in the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: NYU Langone Brooklyn, Brooklyn, New York
Conditions: Acute Respiratory Distress Syndrome, Adult
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Recruiting
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Roswell Park, Buffalo, New York
Conditions: Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Recruiting
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
10/02/2024
Locations: Research Site, New York, New York
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
Cannabis Use and Outcomes in Black and White Patients With Cancer
Recruiting
The goal of the observational study is to learn how black and white patients with solid tumor cancer use cannabis, opioids and tobacco. The investigators are using momentary ecological assessment through a smart phone app and surveys to assess patient-reported pain and other symptoms as to inform clinical practice and guidelines for underrepresented populations.
Gender:
ALL
Ages:
Between 21 years and 99 years
Trial Updated:
10/02/2024
Locations: University at Buffalo, Buffalo, New York
Conditions: Cancer
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Recruiting
This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent). Anti-CD40 CDX-1140 works by stimulating certain immune cells within the tumor and, when combined with other immunotherapy treatments, may increase antitumor antibody production. Immunotherapy with monoclonal antibodies, such as pembrolizumab and bevacizumab, may help the body's immune system, an... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/02/2024
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/02/2024
Locations: Northwell Health, Lake Success, New York
Conditions: HER2-positive Advanced Solid Tumor